4 Results for "

PD176252

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "PD176252" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-103286
CAS No.: 204067-01-6
Purity:  99.38%
Target:  

Bombesin Receptor

Research Areas:  

Cancer

PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
loading...
    loading...
Cat. No.: HY-103286R
CAS No.: 204067-01-6
Research Areas:  

Cancer

PD176252 (Standard) is the analytical standard of PD176252 (HY-103286). This product is intended for research and analytical applications. PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
loading...
    loading...
Cat. No.: HY-115974
CAS No.: 3052544-28-9
Target:  

Bombesin Receptor

Research Areas:  

Cancer

GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis, with anticancer activity .
loading...
    loading...
Cat. No.: HY-115975
CAS No.: 3052544-42-7
Target:  

Bombesin Receptor

Research Areas:  

Cancer

GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity .
loading...
    loading...